For hospitalization because of congestive heart failure, a consistent 27–35% reduction was seen with all SGLT-2 Is1–4, but also with efpeglenatide (by 39%; AMPLITUDE-O16). This evidence concerns the gene SLC5A2 and congestive heart failure.